| Active ingredient (INN) | Liraglutide |
|---|---|
| Brand names | SAXENDA liraglutide |
| Therapeutic category | Auto-created by Therapeutic Goods Administration — Medicine Shortages scraper |
| Controlled substance | No |
| Marketing-authorisation holders | Novo Nordisk Pharmaceuticals Pty Ltd, HIKMA PHARMACEUTICALS USA INC., Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) |
| Registrations on file | 5 |
| Patient information leaflet (PIL) | Not on file |
| Summary of product characteristics (SPC) | Not on file |
| Product | Strength | Form | Market | MA holder | Status |
|---|---|---|---|---|---|
| XULTOPHY insulin degludec | 100 units | — | 🇦🇺 AU | Novo Nordisk Pharmaceuticals Pty Ltd | Active |
| Liraglutide | 6mg/mL | injection | 🇺🇸 US | HIKMA PHARMACEUTICALS USA INC. | Active |
| VICTOZA liraglutide | 6mg | — | 🇦🇺 AU | Novo Nordisk Pharmaceuticals Pty Ltd | Active |
| SAXENDA liraglutide | 6mg | — | 🇦🇺 AU | Novo Nordisk Pharmaceuticals Pty Ltd | Active |
| Liraglutide | 18mg/3mL | injection | 🇺🇸 US | Hybio Pharmaceutical Co., Ltd. (Pingshan Factory) | Active |